GlassScriptPhysician profile
Michael S Lewis
NPI 1306047139
$220,478.23
in general payments reported to CMS, 2019-2025
9 companies · $137K in 2025
The $137K reported for 2025 was more than what 99% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $581 · 2020: $17.04 · 2021: $29.95 · 2022: $137 · 2023: $162 · 2024: $83K · 2025: $137K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $219K · Food and Beverage: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $219,373.40 |
| Food and Beverage | $340.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exthera Medical Corporation | $219,373.40 | 2024-2025 | |
| Genzyme Corporation | $429.95 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $272.74 | 2019-2024 | Xifaxan |
| Abbvie INC. | $166.67 | 2021-2022 | |
| United Therapeutics Corporation | $100.98 | 2025 | |
| Myriad Women'S Health, INC. | $96.77 | 2023 | Myrisk |
| Sandoz INC. | $20.68 | 2019 | |
| Csl Behring | $17.04 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.